TMPRSS6 siRNA Modification for Silencing with Lower Off-Target Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for disorders associated with TMPRSS6 expression, such as beta-thalassemia and polycythemia, are limited, and there is an urgent need for novel siRNA-based therapies that can effectively inhibit TMPRSS6 expression to regulate iron homeostasis and alleviate symptoms of iron overload with reduced off-target activity.
Innovation Solution
Development of double-stranded siRNAs with specific nucleotide sequences and modifications, including 2'-O-methyl-modified nucleotides and 2'-fluoro-modified nucleotides, and conjugation with N-acetylgalactosamine derivatives for targeted delivery, to inhibit TMPRSS6 expression and enhance target silencing efficiency while minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic options are used for TMPRSS6-related disorders, then treatment is available, but therapeutic efficacy is limited and off-target effects occur
Solution Approach 1:
The patent applies local quality by introducing specific chemical modifications at particular positions within the siRNA molecule. Different nucleotides are modified with 2'-O-methyl or 2'-fluoro groups at specific positions (e.g., positions 1-3 and 19-21 of the sense strand), creating localized property changes that enhance stability and reduce off-target effects without compromising target specificity
Solution Approach 2:
The patent employs composite materials by combining multiple modified nucleotide types (2'-O-methyl, 2'-fluoro) with different functional groups and linkers within a single siRNA molecule. This composite structure integrates the stabilizing effects of different modifications to achieve both high efficacy and reduced off-target activity
2Productivity
If siRNA is designed to inhibit TMPRSS6 expression, then iron homeostasis is regulated, but delivery efficiency and target specificity must be optimized
Solution Approach 1:
The patent uses GalNAc (N-acetylgalactosamine) as an intermediary conjugate attached to the siRNA molecule. This GalNAc conjugate acts as a mediator that facilitates specific binding to asialoglycoprotein receptors on hepatocytes, enabling efficient and targeted delivery of the siRNA to the liver where TMPRSS6 is expressed, thereby enhancing both delivery efficiency and target specificity
3Duration of action of stationary object
If siRNA modifications are introduced to enhance stability, then duration of action is extended, but molecular complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying the type (2'-O-methyl vs. 2'-fluoro), position, and number of nucleotide modifications to optimize siRNA stability. By changing these molecular parameters at specific positions, the patent achieves extended duration of action and enhanced stability while managing molecular complexity through structured modification patterns
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed siRNAs demonstrate robust in vitro and in vivo efficacy in inhibiting TMPRSS6 expression, leading to increased hepcidin concentration and decreased serum iron levels, providing therapeutic potential for disorders like thalassemia and polycythemia.
Implementation Method 1
The siRNA comprises a sense strand and an antisense strand, which form a double-stranded structure through base pairing
Implementation Method 2
including 2'-O-methyl-modified nucleotides and 2'-fluoro-modified nucleotides
Implementation Method 3
conjugation with N-acetylgalactosamine derivatives for targeted delivery
Implementation Method 4
Small interfering RNA (siRNA) or short single-stranded RNA such as microRNA (miRNA) forms complexes with the RNA-induced silencing complex (RISC), and subsequently binds to complementary mRNA, which is then cleaved with the help of ribonucleases to inhibit the expression of specific genes
Implementation Method 5
binds to complementary mRNA, which is then cleaved with the help of ribonucleases
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides an siRNA or a pharmaceutically acceptable salt thereof for inhibiting TMPRSS6 expression in human cells, as well as appropriate modifications of the siRNA to enhance target silencing efficiency and minimize off-target activity. The invention further provides biological agent or pharmaceutical compositions containing the foregoing siRNA for inhibiting TMPRSS6 expression. Through a series of in vitro and in vivo experiments, the present invention has identified siRNA sequences with potent biological activity in suppressing TMPRS S6 expression, demonstrating higher efficacy than TMPRSS6-HCM-9, which is currently the most advanced siRNA in clinical development. These findings support the potential clinical application of the invention in treating disorders associated with dysregulated TMPRSS6 expression or diseases related to iron excess or iron overload, demonstrating significant therapeutic potential.